Identifying Tumor Antigens in Ovarian Cancer
Author Information
Author(s): Luo L-Y, Herrera I, Soosaipillai A, Diamandis E P
Primary Institution: Mount Sinai Hospital, Toronto, ON, Canada
Hypothesis
Can serological screening of recombinant cDNA expression libraries identify tumor antigens in ovarian cancer?
Conclusion
The study found that heat shock protein 90 autoantibodies are frequently present in late-stage ovarian cancer, suggesting it may serve as a novel biomarker and vaccine target.
Supporting Evidence
- Twelve tumor antigens were identified, including heat shock protein 90.
- Hsp90 autoantibodies were found in 32% of stage III/IV ovarian cancer patients.
- The study suggests hsp90 could be a novel biomarker for ovarian cancer.
Takeaway
Researchers looked for special proteins in ovarian cancer that can help doctors find and treat the disease better. They found one protein, hsp90, that shows up a lot in advanced cases.
Methodology
The study used serological analysis of recombinant cDNA expression libraries to identify tumor antigens and immunoassays to detect autoantibodies against hsp90.
Potential Biases
Potential bias in patient selection and the reliance on serological responses may affect the generalizability of the findings.
Limitations
The study primarily focused on a limited number of cancer types and may not represent all ovarian cancer cases.
Participant Demographics
Included 22 normal females, 32 ovarian cancer patients (22 stage III/IV, 10 stage I/II), and patients with other cancers and benign diseases.
Statistical Information
P-Value
0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website